Primary and Secondary Tumors of the Parotid Gland: Clinical Features and Prognosis

Abstract

Primary and secondary malignant tumors can affect the parotid gland. The aim of this retrospective study was to evaluate the clinical features and prognosis of malignant epithelial tumors of the parotid gland. In particular, a comparison between primary and secondary cancer and survival analyses were performed. Eighteen patients with primary cancer and fifteen with intraparotid metastasis from cutaneous squamous cell carcinoma were included. A chart review was performed to collect clinical data (age, sex, smoking, alcohol consumption, tumor stage, type of surgical procedure, complications, recurrence and death). The majority of primary tumors were early (T1-2 N0, 83%) with mucoepidermoid carcinoma being the most common (33%). Secondary tumors were mostly staged P2 (53%) and N0 (67%). Subjects with secondary tumors were older than those with primary cancer. Post-operative permanent facial palsy was observed in 5 patients (17%) with primary cancer and 9 (60%) with secondary tumors (p = 0.010). Two-year overall survival for primary and secondary parotid cancer was 76.58% and 43.51%, respectively (p = 0.048), while 2-year disease-free survival was 76.05% and 38.50%, respectively (p = 0.152). In conclusion, secondary cancer of the parotid gland has worse survival than primary tumors. In the future, the implementation of multimodality treatment of intraparotid metastases is necessary to improve oncologic outcomes.

Long‐term follow‐up and prognostic analysis of parotid tumors in children and adolescents

“…Among the malignancies, mucoepidermoid carcinoma was the most common, followed by acinic cell carcinoma, which is slightly different from the pathological types reported in adults, as mucoepidermoid carcinoma, adenoid cystic carcinoma, and parotid duct carcinoma are the most common in adults 12‐16 . Compared with adults, high‐grade malignant tumors, such as squamous cell carcinoma and parotid duct carcinoma, are less common in children and adolescents, 12,17 and only 1 case of squamous cell carcinoma was diagnosed and no case of parotid duct carcinoma was diagnosed in our group.…”

“…Of these, most (65.2%) patients with malignant tumors received total parotidectomy, and this proportion was lower than the proportion of adults with malignant parotid glands reported in the relevant literatures (83.4%-87.1%), which may be due to a relatively higher proportion of high-grade tumors (such as squamous cell carcinoma, parotid duct carcinoma, and sarcomas) in adults. 12,17 F I G U R E 2 Overall survival of parotid tumors.…”

Nomogram based on immune-inflammatory indicators and age-adjusted Charlson comorbidity index score to predict prognosis of postoperative parotid gland carcinoma patients

“…PGC is a rare head and neck tumor with remarkable heterogeneity, which results highly variable in treatment outcomes. Generally, the AJCC stage system was the widely-used PGC has been studied previously by various researchers from different aspects [4,6,14,15]. In this study, we obtained the total cases from two tertiary hospitals in China and focused on the role of immune-inflammatory-nutrition indicators and ACCI in PGC patients which had not been noticed before.…”

Nomogram based on immune-inflammatory indicators and age-adjusted charlson comorbidity index score to predict prognosis of postoperative parotid gland carcinoma patients

“…Therefore, it is important to identify more prognostic factors and develop a comprehensive and applicable tool to upregulate the efficiency in predicting prognosis, which can be helpful for clinicians in making proper clinical decisions. [4,6,12,14,15]. However, the role of immune-inflammatory-nutrition indicators and Age-Adjusted Charlson Comorbidity Index (ACCI) in PGC patients has not been studied so far.…”